Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
Signorelli C, Chilelli MG, Giannarelli D, Basso M, Calegari MA, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: ruggeri em. Cancers (Basel). 2023 Dec 8;15(24):5758. doi: 10.3390/cancers15245758. Cancers (Basel). 2023. PMID: 38136304 Free PMC article.
Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis.
Signorelli C, Amodio PM, Chilelli MG, Santoro R, Schirripa M, Ranalli TV, Pessina G, Giron Berrios JR, Natoni F, Virtuoso A, Primi F, Mazzotta M, Nelli F, Fabbri A, Marrucci E, Ruggeri EM. Signorelli C, et al. Among authors: ruggeri em. Cureus. 2022 Oct 23;14(10):e30607. doi: 10.7759/cureus.30607. eCollection 2022 Oct. Cureus. 2022. PMID: 36299600 Free PMC article.
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
Ruggeri EM, Nelli F, Giannarelli D, Fabbri A, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Fiore C, Panichi V, Topini G, Silvestri MA. Ruggeri EM, et al. Sci Rep. 2022 Dec 19;12(1):21908. doi: 10.1038/s41598-022-25558-8. Sci Rep. 2022. PMID: 36535985 Free PMC article.
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10. Cancer Immunol Immunother. 2023. PMID: 37428196 Free PMC article.
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.
Nelli F, Signorelli C, Fabbri A, Giannarelli D, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Cancers (Basel). 2023 Jul 14;15(14):3625. doi: 10.3390/cancers15143625. Cancers (Basel). 2023. PMID: 37509286 Free PMC article.
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study.
Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Marrucci E, Fiore C, Giron Berrios JR, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Caterini L, Farinelli S, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Clin Exp Med. 2024 Jan 20;24(1):13. doi: 10.1007/s10238-023-01263-2. Clin Exp Med. 2024. PMID: 38244147 Free PMC article.
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. eCollection 2023. Front Oncol. 2023. PMID: 38023235 Free PMC article.
101 results